2. Search Result
Search Result
Results for "

polymorphonuclear+leukocytes

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

2

Peptides

8

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-129905
    L-Leucyl-L-Leucine methyl ester hydrochloride
    Maximum Cited Publications
    18 Publications Verification

    LLOMe hydrochloride; Leu-Leu methyl ester hydrochloride; H-Leu-Leu-OMe hydrochloride

    		 Endogenous Metabolite Inflammation/Immunology
    L-Leucyl-L-Leucine methyl ester (LLOMe) hydrochloride, a dipeptide condensation product of L-leucine methyl ester generated by human monocytes or polymorphonuclear leukocytes, selectively eliminates lymphocytes with cytotoxic potential. L-Leucyl-L-Leucine methyl ester hydrochloride also can induce endolysosomal pathway stress .
    L-Leucyl-L-Leucine methyl ester hydrochloride
  • HY-129905A
    L-Leucyl-L-Leucine methyl ester hydrobromide
    Maximum Cited Publications
    18 Publications Verification

    LLOMe hydrobromide; Leu-Leu methyl ester hydrobromide; H-Leu-Leu-OMe hydrobromide

    		 Endogenous Metabolite Inflammation/Immunology
    L-Leucyl-L-Leucine methyl ester (LLOMe) hydrobromide, a dipeptide condensation product of L-leucine methyl ester generated by human monocytes or polymorphonuclear leukocytes, selectively eliminates lymphocytes with cytotoxic potential. L-Leucyl-L-Leucine methyl ester hydrobromide also can induce endolysosomal pathway stress .
    L-Leucyl-L-Leucine methyl ester hydrobromide
  • HY-114041
    Resolvin E1
    2 Publications Verification

    RvE1

    		 Endogenous Metabolite Inflammation/Immunology
    Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
    Resolvin E1
  • HY-W016733
    D-Citrulline

    H-D-Cit-OH

    		 Endogenous Metabolite Cardiovascular Disease
    D-Citrulline (H-D-Cit-OH) is a stereoisomer of L-citrulline (HY-N0391). D-Citrulline significantly attenuates polymorphonuclear leukocyte (PMN)-induced cardiac contractile dysfunction in the isolated perfused rat heart subjected to ischemia/reperfusion via a non-NO-mediated mechanism .
    D-Citrulline
  • HY-N3945
    Glaucine

    O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396

    		 Phosphodiesterase (PDE) Calcium Channel MMP NF-κB Inflammation/Immunology Cancer
    Glaucine (O,O-Dimethylisoboldine) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine holds potential for research in asthma and breast cancer .
    Glaucine
  • HY-148141
    JPE-1375
    4 Publications Verification

    		 Complement System Inflammation/Immunology
    JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 μM) and reduces TNF levels (EC50=4.5 μM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases .
    JPE-1375
  • HY-P10738
    N-Formyl-MMYALF

    		Formyl Peptide Receptor (FPR) Infection
    N-Formyl-MMYALF is a potent mitochondrial N-formyl peptide (mtFP) that has the activity of depleting calcium ions in the endoplasmic reticulum. N-Formyl-MMYALF can inhibit the FPR-1-mediated chemotactic response of polymorphonuclear leukocytes (PMNs) to bacterial peptides .
    N-Formyl-MMYALF
  • HY-106200
    CJ-13,610

    		Lipoxygenase Inflammation/Immunology
    CJ-13,610, a nonredox-type 5-LO inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC50 of about 70 nM . PMNL: polymorphonuclear leukocytes; AA: arachidonic acid
    CJ-13,610
  • HY-120314
    GEA 3162

    		Apoptosis Caspase Endogenous Metabolite Inflammation/Immunology
    GEA 3162 is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 can be used for research on inflammatory conditions such as gastric ulcers .
    GEA 3162
  • HY-114041S
    Resolvin E1-d4

    RvE1-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Inflammation/Immunology
    Resolvin E1-d4 (RvE1-d4) is deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
    Resolvin E1-d4
  • HY-N9970
    Apigenin 7-O-β-D-glucuronide ethyl ester

    		Others Inflammation/Immunology
    Apigenin 7-O-β-D-glucuronide ethyl ester is a flavonoid glucuronate ester that can be isolated from Scutellaria regeliana. Apigenin 7-O-β-D-glucuronide ethyl ester possesses anti-inflammatory activity on the release of β-glucuronidase from rat polymorphonuclear leukocytes (PNMs) induced by platelet activating-factor. Apigenin 7-O-β-D-glucuronide ethyl ester can be used for anti-inflammatory research .
    Apigenin 7-O-β-D-glucuronide ethyl ester
  • HY-114041S1
    Resolvin E1-d4-1

    RvE1-d4-1

    		 Isotope-Labeled Compounds Endogenous Metabolite Inflammation/Immunology
    Resolvin E1-d4-1 is the deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
    Resolvin E1-d4-1
  • HY-N17236
    Forsyshiyanine A

    		β-glucuronidase Influenza Virus RSV Infection
    Foryshiyanine A is a triterpenoid alkaloid. Foryshiyanine A possesses anti-inflammatory activity, inhibiting the release of β-glucuronidase from rat polymorphonuclear leukocytes. Foryshiyanine A exhibits antiviral activity, with an EC50 of 4.5 μM against respiratory syncytial virus (RSV) and an IC50 of 7.3 μM against influenza A virus (H1N1). Foryshiyanine A reduces viral load by disrupting viral replication and entry. Foryshiyanine A may be used for the researches of inflammation and infection .
    Forsyshiyanine A
  • HY-N3945R
    Glaucine (Standard)

    O,O-Dimethylisoboldine (Standard); S-(+)-Glaucine (Standard); NSC 34396 (Standard)

    		 Reference Standards Phosphodiesterase (PDE) Calcium Channel Adrenergic Receptor Dopamine Receptor Influenza Virus Infection Inflammation/Immunology
    Glaucine (Standard) is the analytical standard of Glaucine. This product is intended for research and analytical applications. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor with Kis of 3.4 μM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca2+ entry blocker, and a weak dopamine D1 and D2 receptor antagonist. Glaucine has antioxidative and antiviral activities .
    Glaucine (Standard)
  • HY-106899
    MK 287

    		Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
    MK 287
  • HY-113484
    Leukotriene B5

    LTB5

    		 Leukotriene Receptor Cancer
    Leukotriene B5 (LTB5) is a leukotriene with diverse biological activities. It is a metabolite of eicosapentaenoic acid formed through the 5-lipoxygenase (5-LO) pathway. LTB5 increases contraction of bullfrog lung strips ex vivo in a concentration-dependent manner. In vivo, LTB5 (100 nM) reduces tumor volume in mice injected with Tm1 murine melanoma cells. LTB5 also elicits chemokinesis and lysosomal enzyme release from polymorphonuclear leukocytes (PMNLs) 20- to 30-fold less, and induces platelet aggregation 8-fold less, potently than LTB4.
    Leukotriene B5
  • HY-112553
    HZ52

    		Lipoxygenase Inflammation/Immunology
    HZ52 is a potent, reversible 5-lipoxygenase inhibitor, blocking leukotriene synthesis with an IC50 of 0.7 μM in intact human polymorphonuclear leukocytes .
    HZ52
  • HY-118261
    L 659286

    		Elastase Inflammation/Immunology
    L 659286 is an inhibitor of human polymorphonuclear leukocyte elastase (PMN elastase) (Ki=0.4 μM). Intratracheal injection of L 659286 can induce lung injury in hamsters.
    L 659286
  • HY-105176A
    (R)-Ontazolast

    (R)-BIRM-270

    		 Leukotriene Receptor Inflammation/Immunology
    (R)-Ontazolast ((R)-BIRM-270) is a potent inhibitor of leukotriene biosynthesis, effectively blocking the release of arachidonic acid and demonstrating an impressive IC50 value of 0.001 microM in human polymorphonuclear leukocytes.
    (R)-Ontazolast
  • HY-120876
    L-680833

    		Beta-lactamase Elastase Inflammation/Immunology
    L-680833 is a monocyclic β-lactam inhibitor of human polymorphonuclear leukocyte elastase (PMNE) inhibitor. L-680833 can be used for the study of PMNE-damaged tissue diseases .
    L-680833
  • HY-N2247A
    (+)-Guaiacin

    		Platelet-activating Factor Receptor (PAFR) Metabolic Disease
    (+)-Guaiacin is a compound extracted of the bark of Machilus wangchiana Chun. (Lauraceae). (+)-Guaiacin shows potent in vitro activities against the release of β-glucuronidase in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activating factor (PAF) .
    (+)-Guaiacin
  • HY-101579
    LY 178002

    		COX Lipoxygenase Phospholipase Inflammation/Immunology
    LY 178002 is a potent inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2, with IC50 of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.
    LY 178002
  • HY-105933
    L-652343

    		Lipoxygenase COX Leukotriene Receptor Inflammation/Immunology
    L-652343 is a dual cyclooxygenase/lipoxygenase inhibitor. L-652343 can inhibit the production of LTB4 in isolated human polymorphonuclear leukocytes treated with Calcimycin (HY-N6687) (IC50: 1.4 μM), but it is inactive in whole blood. L-652343 can be used in the research of inflammatory and immune diseases .
    L-652343
  • HY-167715
    Traxanox

    		Histamine Receptor Phosphodiesterase (PDE) Inflammation/Immunology
    Traxanox is an orally available diuretic that enhances phagocytosis of yeast granules by mouse peritoneal macrophages and rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox inhibits IgE-mediated histamine release and cyclic AMP phosphodiesterase activity.Traxanox exhibits anti-inflammatory activity, as it inhibits the anaphylactoid reaction and reduces pleural fluid accumulation in experimental models of inflammation. Traxanox also demonstrates a synergistic effect when combined with hydrocortisone or indomethacin in suppressing adjuvant arthritis in rats.
    Traxanox
  • HY-134123
    Lipoxin B4 methyl ester

    LXB4 methyl ester

    		 Drug Intermediate Leukotriene Receptor Metabolic Disease
    Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4. LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 (LTB4; Item No. 20110) and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM.
    Lipoxin B4 methyl ester
  • HY-118652
    Δ17-6-keto Prostaglandin F1α

    ω-3 6-keto PGF2α

    		 Prostaglandin Receptor Metabolic Disease
    Δ17-6-keto Prostaglandin F1α (Δ17-6-keto PGF1α) is a cyclooxygenase (COX) product of eicosapentaenoic acid (EPA) in various tissues such as seminal vesicles, lung, Polymorphonuclear leukocytes, and ocular tissues. Δ17-6-keto PGF1α and other 3-series COX products from EPA, such as PGF3α, PGE3, and thromboxane B3, may be involved in the reduced incidence of glaucoma in patients on a marine-rich (EPA-rich) diet.
    Δ17-6-keto Prostaglandin F1α
  • HY-120314A
    GEA 3162 hydrochloride

    		Apoptosis Caspase Endogenous Metabolite Inflammation/Immunology
    GEA 3162 hydrochloride is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 hydrochloride significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 hydrochloride induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 hydrochloride has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 hydrochloride can be used for research on inflammatory conditions such as gastric ulcers .
    GEA 3162 hydrochloride
  • HY-117811
    (R,R)-MK 287

    L-680574

    		 Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    (R,R)-MK 287 (L-680574) is a tetrahydrofuran derivative that potently inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with Ki values of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50=56 nM) and elastase release from PMNs (ED50=4.4 nM). (R,R)-MK 287 inhibits PAF-induced lethality in mice (ED50=0.8 mg/kg, po) and PAF-induced bronchospasm in guinea pigs (ED50=0.18 mg/kg) .
    (R,R)-MK 287
  • HY-106899A
    (rel)-MK 287

    (rel)-L-680573

    		 Platelet-activating Factor Receptor (PAFR) Others
    (rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
    (rel)-MK 287
  • HY-157253
    13(S)-HODE-biotin

    		Drug Metabolite Metabolic Disease
    13(S)-HODE is the lipoxygenase metabolite of Linoleic acid (HY-N0729). 13(S)-HODE modulates the platelet-activating factor, leukotriene B4, and formyl-Met-Leu-Phe-induced calcium influx in human polymorphonuclear leukocytes.
    13(S)-HODE-biotin
  • HY-W923355
    1,2,3-Trieicosapentaenoyl glycerol

    EPA-TG; Glycerol trieicosapentaenoate; TG(20:5/20:5/20:5)

    		 Others Others
    1,2,3-Trieicosapentaenoyl glycerol (EPA-TG) is a glycerol ester that can be obtained by the reaction of polyunsaturated fatty acids or lower alkyl esters with glycerol catalyzed by alkoxide ions . After two intravenous injections of the EPA-TG emulsion into rabbits, the EPA content in plasma and platelet phospholipids increased markedly . In another study, by administering the EPA-TG emulsion, the production of leukotriene B4 by polymorphonuclear leukocytes in rabbits was reduced by 40% .
    1,2,3-Trieicosapentaenoyl glycerol
  • HY-106200R
    CJ-13,610 (Standard)

    		Reference Standards Lipoxygenase Inflammation/Immunology
    CJ-13,610 (Standard) is the analytical standard of CJ-13,610 (HY-106200). This product is intended for research and analytical applications. CJ-13,610, a nonredox-type 5-LO inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC50 of about 70 nM . PMNL: polymorphonuclear leukocytes; AA: arachidonic acid
    CJ-13,610 (Standard)
  • HY-145474
    17(R)-Resolvin D1 methyl ester

    		Endogenous Metabolite Inflammation/Immunology
    17(R)-Resolvin D1 methyl ester is the methyl ester of Resolvin D1 (RvD1) (HY-125527) induced by Aspirin (HY-14654) with the 17R epimer (AT-RvD1). RvD is a regulator of transendothelial migration of human polymorphonuclear leukocytes and an anti-inflammatory agent. The 17R-trihydroxy-4Z of RvD1 also blocks transendothelial migration of human neutrophils (EC50 approximately 30 nM). AT-RvD1 is an effective form that protects against the rapid inactivation of Resolvin D1 .
    17(R)-Resolvin D1 methyl ester

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: